D. E. Shaw & Co., Inc. Repligen Corp Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Repligen Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 20,000 shares of RGEN stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,000

Previous 45,000 55.56%

Holding current value

$2.53 Million

Previous $6.48 Million 60.72%

% of portfolio

0.0%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$127.24 - $174.24 $311,356 - $426,365	-2,447 Reduced 48.37%	2,612 $332,000
Q4 2024 Feb 14, 2025	BUY	$123.41 - $160.92 $624,331 - $814,094	5,059 New	5,059 $728,000
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $14.3 Million - $21.8 Million	-119,042 Reduced 94.92%	6,369 $802,000
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $7.33 Million - $8.95 Million	42,926 Added 52.04%	125,411 $23.1 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $7.75 Million - $12.6 Million	67,905 Added 465.74%	82,485 $14.8 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $438,406 - $557,595	3,159 Added 27.66%	14,580 $2.32 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $1.58 Million - $2.06 Million	11,421 New	11,421 $1.62 Million
Q4 2022 Feb 14, 2023	SELL	$162.42 - $220.56 $34,595 - $46,979	-213 Reduced 3.81%	5,379 $910,000
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $675,368 - $1.08 Million	-4,210 Reduced 42.95%	5,592 $1.05 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $679,906 - $908,700	4,833 Added 97.26%	9,802 $1.59 Million
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $214,382 - $343,086	1,330 Added 36.55%	4,969 $935,000
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $2.29 Million - $2.81 Million	-9,231 Reduced 71.72%	3,639 $964,000
Q3 2021 Nov 15, 2021	BUY	$194.77 - $324.21 $2.51 Million - $4.17 Million	12,870 New	12,870 $3.72 Million
Q2 2021 Aug 16, 2021	SELL	$165.87 - $220.95 $924,891 - $1.23 Million	-5,576 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$180.37 - $226.26 $6.49 Million - $8.14 Million	-35,998 Reduced 86.59%	5,576 $1.08 Million
Q4 2020 Feb 16, 2021	SELL	$148.08 - $206.57 $11.4 Million - $15.9 Million	-77,007 Reduced 64.94%	41,574 $7.97 Million
Q3 2020 Nov 16, 2020	BUY	$122.51 - $158.27 $11.3 Million - $14.7 Million	92,601 Added 356.43%	118,581 $17.5 Million
Q2 2020 Aug 14, 2020	SELL	$94.33 - $140.48 $2.36 Million - $3.51 Million	-25,018 Reduced 49.06%	25,980 $3.21 Million
Q1 2020 May 15, 2020	SELL	$84.96 - $109.14 $4.69 Million - $6.02 Million	-55,193 Reduced 51.98%	50,998 $4.92 Million
Q4 2019 Feb 14, 2020	BUY	$73.84 - $93.08 $829,370 - $1.05 Million	11,232 Added 11.83%	106,191 $9.82 Million
Q3 2019 Nov 14, 2019	SELL	$76.65 - $95.51 $9.05 Million - $11.3 Million	-118,011 Reduced 55.41%	94,959 $7.28 Million
Q2 2019 Aug 14, 2019	SELL	$54.2 - $85.95 $2.76 Million - $4.38 Million	-51,001 Reduced 19.32%	212,970 $18.3 Million
Q1 2019 May 15, 2019	SELL	$49.45 - $62.8 $131,487 - $166,985	-2,659 Reduced 1.0%	263,971 $15.6 Million
Q4 2018 Feb 14, 2019	BUY	$48.26 - $68.88 $11.1 Million - $15.8 Million	229,128 Added 610.98%	266,630 $14.1 Million
Q3 2018 Nov 14, 2018	BUY	$46.8 - $58.97 $1.76 Million - $2.21 Million	37,502 New	37,502 $2.08 Million
Q2 2018 Aug 14, 2018	SELL	$35.26 - $47.04 $291,952 - $389,491	-8,280 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$30.92 - $37.27 $888,609 - $1.07 Million	-28,739 Reduced 77.63%	8,280 $300,000
Q4 2017 Feb 14, 2018	BUY	$32.53 - $38.92 $969,816 - $1.16 Million	29,813 Added 413.72%	37,019 $1.34 Million
Q3 2017 Nov 14, 2017	BUY	$36.98 - $46.06 $266,477 - $331,908	7,206	7,206 $276,000

Others Institutions Holding RGEN

# of Institutions

495

Shares Held

57.6M

Call Options Held

75.6K

Put Options Held

521K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.03B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account